Clinical Trial Details
| Trial ID: | L7233 |
| Source ID: | NCT00099333 |
| Associated Drug: | Exenatide |
| Title: | Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: exenatide|DRUG: Insulin |
| Outcome Measures: | Primary: Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16, Change in HbA1c from Baseline study termination (Week 16), Baseline, Week 16 | |
| Sponsor/Collaborators: | Sponsor: AstraZeneca | Collaborators: Eli Lilly and Company |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 49 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2004-02 |
| Completion Date: | 2005-08 |
| Results First Posted: | |
| Last Update Posted: | 2015-02-23 |
| Locations: | Research Site, Chula Vista, California, United States|Research Site, Butte, Montana, United States|Research Site, Portland, Oregon, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States |
| URL: | https://clinicaltrials.gov/show/NCT00099333 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|